Oligonucleotide inhibitors of cancer cell proliferation

A pharmaceutical composition for the treatment of cancer comprising an oligonucleotide that is targeted to a nucleic acid encoding human K-RAS oncogene wherein said oligonucleotide comprises SEQ. ID. NO:

• 1, 2, 6 or 7.

A pharmaceutical composition for the treatment of cancer, wherein said cancer is at least one of the group of colon cancer, hematologic cancer, lung cancer, ovarian cancer, prostate cancer, skin cancer, and thyroid cancer, comprising an oligonucleotide that is targeted to a nucleic acid encoding human K-RAS oncogene wherein said oligonucleotide comprises SEQ. ID. NO:

• 1, 2, 6 or 7

A pharmaceutical composition for the treatment of ovarian cancer comprising an oligonucleotide that is targeted to a nucleic acid encoding human K-RAS oncogene wherein said oligonucleotide comprises SEQ. ID. NO:

• 1, 2, 6 or 7.

A method of inhibiting the proliferation of cancer cells comprising contacting said cancer cells with an effective amount of an oligonucleotide comprising SEQ. ID. NO:

• 1, 2, 6 or 7, whereby proliferation of the cancer cells is inhibited.

A method of inhibiting the proliferation of cancer cells, wherein said cancer cells are at least one of the group of colon cancer cells, hematologic cancer, lung cancer cells, ovarian cancer cells, prostate cancer cells, skin cancer cells, and thyroid cancer cells, comprising contacting said cancer cells with an effective amount of an oligonucleotide comprising SEQ. ID. NO:

• 1, 2, 6 or 7, whereby proliferation of the cancer cells is inhibited.

A method of inhibiting the proliferation of ovarian cancer cells comprising contacting said cancer cells with an effective amount of an oligonucleotide comprising SEQ. ID. NO:

• 1, 2, 6 or 7, whereby proliferation of the cancer cells is inhibited.

A method of modulating the expression of mutation-activated K-RAS oncogene in tissues or cells containing a mutation-activated K-RAS oncogene comprising contacting said tissues or cells containing a mutation-activated K-RAS oncogene with an effective amount of an oligonucleotide comprising SEQ. ID. NO:

• 1, 2, 6 or 7 whereby expression of mutation-activated K-RAS is modulated.

A method of modulating the expression of mutation-activated K-RAS oncogene in tissues or cells containing a mutation-activated K-RAS oncogene, wherein said tissues or cells containing a mutation-activated K-RAS oncogene are at least one of the group of colon cancer cells, hematologic cancer, lung cancer cells, ovarian cancer cells, prostate cancer cells, skin cancer cells, and thyroid cancer cells, comprising contacting said tissues or cells containing a mutation-activated K-RAS oncogene with an effective amount of an oligonucleotide comprising SEQ. ID. NO:

• 1, 2, 6 or 7 whereby expression of mutation-activated K-RAS is modulated.

A method of modulating the expression of mutation-activated K-RAS oncogene in ovarian tissues or cells containing a mutation-activated K-RAS oncogene comprising contacting said ovarian tissues or cells containing a mutation-activated K-RAS oncogene with an effective amount of an oligonucleotide comprising SEQ. ID. NO:

• 1, 2, 6 or 7 whereby expression of mutation-activated K-RAS is modulated.

An oligonucleotide 8 to 15 nucleotides in length which is targeted to a nucleic acid encoding human K-RAS and which is capable of modulating K-RAS expression, wherein said oligonucleotide is complemenatary to a region between nucleotides 138 and 147 of human K-RAS.